<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006751.pub4" GROUP_ID="CF" ID="071506100911335286" MERGED_FROM="" MODIFIED="2014-05-14 08:47:34 +0100" MODIFIED_BY="Nikki Jahnke" REVIEW_NO="0082" REVMAN_SUB_VERSION="5.2.11 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2014-05-13 12:10:43 +0100" MODIFIED_BY="Nikki Jahnke">
<TITLE>Vitamin A supplementation for cystic fibrosis</TITLE>
<CONTACT>
<PERSON ID="2C663C3482E26AA200C1C7C4ED66C98A" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Catherine</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Bonifant</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Specialist Dietitian</POSITION>
<EMAIL_1>Catherine_Bonifant@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nutrition and Dietetics</DEPARTMENT>
<ORGANISATION>Royal Children's Hospital</ORGANISATION>
<ADDRESS_1>Lower Ground Floor, South Tower</ADDRESS_1>
<ADDRESS_2>Herston Road</ADDRESS_2>
<CITY>Herston</CITY>
<ZIP>4029</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 3636 7442</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 3636 1883</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-05-13 12:10:43 +0100" MODIFIED_BY="Nikki Jahnke">
<PERSON ID="2C663C3482E26AA200C1C7C4ED66C98A" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Catherine</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Bonifant</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Specialist Dietitian</POSITION>
<EMAIL_1>Catherine_Bonifant@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nutrition and Dietetics</DEPARTMENT>
<ORGANISATION>Royal Children's Hospital</ORGANISATION>
<ADDRESS_1>Lower Ground Floor, South Tower</ADDRESS_1>
<ADDRESS_2>Herston Road</ADDRESS_2>
<CITY>Herston</CITY>
<ZIP>4029</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 3636 7442</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 3636 1883</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2C6934B382E26AA200C1C7C431E1B2A1" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Elizabeth</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shevill</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Nurse Consultant</POSITION>
<EMAIL_1>Elizabeth_Shevill@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Respiratory Medicine</DEPARTMENT>
<ORGANISATION>Royal Children's Hospital</ORGANISATION>
<ADDRESS_1>Level 3, Coles Building</ADDRESS_1>
<ADDRESS_2>Herston Road</ADDRESS_2>
<CITY>Herston</CITY>
<ZIP>4029</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12396" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS>B</MIDDLE_INITIALS>
<LAST_NAME>Chang</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Principal Fellow, NHMRC Pracitioner Fellow</POSITION>
<EMAIL_1>Anne.Chang@menzies.edu.au</EMAIL_1>
<EMAIL_2>Anne.chang@menzies.edu.au</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Child Health Division</DEPARTMENT>
<ORGANISATION>Menzies School of Health Research, Charles Darwin University</ORGANISATION>
<ADDRESS_1>PO Box 41096</ADDRESS_1>
<ADDRESS_2/>
<CITY>Darwin</CITY>
<ZIP>0811</ZIP>
<REGION>Northern Territories</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 36369149</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 36361958</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-05-06 10:52:27 +0100" MODIFIED_BY="Nikki Jahnke">
<UP_TO_DATE>
<DATE DAY="6" MONTH="5" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="4" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="6" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-05-06 10:52:53 +0100" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-05-06 10:52:47 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="6" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>No new studies were included so the conclusions of the review have not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-05-06 10:52:53 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="6" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register did not identify any new studies potentially eligible for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-04-08 16:46:45 +0100" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-04-08 16:46:41 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="7" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register did not identify any new references potentially eligible for inclusion in this review. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-04-08 16:46:45 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="7" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>No new studies were included so the conclusions of the review have not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-05-23 16:35:32 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="1" MONTH="12" YEAR="2009"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register identified a single reference which was excluded (<LINK REF="STD-Wood-2003" TYPE="STUDY">Wood 2003</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-12-01 15:00:08 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="12" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-08-12 14:54:27 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="10" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register did not identify any trials which might be eligible for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-12 14:54:27 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="10" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Royal Children's Hospital Foundation, Brisbane</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Health and Medical Research Council</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-05-13 12:11:46 +0100" MODIFIED_BY="Nikki Jahnke">
<SUMMARY MODIFIED="2014-05-06 10:47:31 +0100" MODIFIED_BY="Nikki Jahnke">
<TITLE>The use of regular vitamin A preparations for children and adults with cystic fibrosis</TITLE>
<SUMMARY_BODY MODIFIED="2014-05-06 10:47:31 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Cystic fibrosis can lead to certain vitamins, such as vitamin A, not being properly absorbed by the body. This can result in problems caused by vitamin deficiency. A lack of vitamin A (vitamin A deficiency) can cause specific problems such as eye and skin problems. It can also be associated with poorer general and respiratory health. Therefore people with cystic fibrosis are usually given regular vitamin A preparations from a very young age. However, too much vitamin A can also cause respiratory and bone problems. The review aimed to show whether giving vitamin A regularly to people with cystic fibrosis is beneficial or not. However, the authors did not find any relevant trials to include in the review. They are therefore unable to draw any conclusions regarding the routine administration of vitamin A supplements and recommend that until further evidence is available, local guidelines are followed regarding this practice.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-05-06 10:42:54 +0100" MODIFIED_BY="Nikki Jahnke">
<ABS_BACKGROUND>
<P>People with cystic fibrosis and pancreatic insufficiency are at risk of fat soluble vitamin deficiency as these vitamins (A, D, E and K) are co-absorbed with fat. Thus, some cystic fibrosis centres routinely administer these vitamins as supplements but the centres vary in their approach of addressing the possible development of deficiencies in these vitamins. Vitamin A deficiency causes predominantly eye and skin problems while supplementation of vitamin A to excessive levels may cause harm to the respiratory and skeletal systems in children. Thus a systematic review on vitamin A supplementation in people with cystic fibrosis would help guide clinical practice.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-05-06 10:42:54 +0100" MODIFIED_BY="Nikki Jahnke">
<P>To determine if vitamin A supplementation in children and adults with cystic fibrosis:<BR/>1. reduces the frequency of vitamin A deficiency disorders;<BR/>2. improves general and respiratory health;<BR/>3. increases the frequency of vitamin A toxicity.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-04-08 16:48:30 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.</P>
<P>Date of the most recent search of the Group's Cystic Fibrosis Trials Register: 07 April 2014.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised or quasi-randomised controlled trials comparing all preparations of oral vitamin A used as a supplement compared to either no supplementation (or placebo) at any dose and for any duration, in children or adults with cystic fibrosis (defined by sweat tests or genetic testing) with and without pancreatic insufficiency.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-12-03 15:55:51 +0000" MODIFIED_BY="Nikki Jahnke">
<P>No relevant studies for inclusion were identified in the search.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-12-01 15:07:34 +0000" MODIFIED_BY="Nikki Jahnke">
<P>No studies were included in this review.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>As there were no randomised or quasi-randomised controlled trials identified, we cannot draw any conclusions on the benefits (or otherwise) of regular administration of vitamin A in people with cystic fibrosis. Until further data are available, country or region specific guidelines on the use of vitamin A in people with cystic fibrosis should be followed. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-05-13 12:11:46 +0100" MODIFIED_BY="Nikki Jahnke">
<BACKGROUND MODIFIED="2014-05-13 12:10:58 +0100" MODIFIED_BY="Nikki Jahnke">
<CONDITION MODIFIED="2014-05-13 12:10:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Cystic fibrosis (CF) is a genetic disorder that affects multiple organs. Pancreatic insufficiency affects up to 90% of people with CF, whereby fat malabsorption occurs and pancreatic enzyme replacement is required to prevent steatorrhoea and malnutrition (<LINK REF="REF-Dodge-2006" TYPE="REFERENCE">Dodge 2006</LINK>). Fat soluble vitamins (A, D, E and K) are co-absorbed with fat and thus deficiency of these vitamins may occur (<LINK REF="REF-Dodge-2006" TYPE="REFERENCE">Dodge 2006</LINK>). Some CF centres routinely administer these vitamins as supplements from the neonatal period, whilst others (few) administer them only later in life or when deficiencies are detected clinically or on routine monitoring.
 While deficiencies may occur from the disease process of CF and insufficient supplementation, vitamin toxicity may also occur from excess supplementation. Both deficiency and excess of these vitamins may lead to specific medical problems (<LINK REF="REF-Dodge-2006" TYPE="REFERENCE">Dodge 2006</LINK>; <LINK REF="REF-Sethuraman-2006" TYPE="REFERENCE">Sethuraman 2006</LINK>).</P>
<P>Vitamin A is an essential nutrient for epithelial cell maintenance and repair in the respiratory, urinary and intestinal tract, immune response, and bone growth (<LINK REF="REF-DAA-2006" TYPE="REFERENCE">DAA 2006</LINK>). Dietary vitamin A (retinol or retinol esters) is found in liver, beef, eggs, fish, the fat of dairy products and vitamin A fortified margarine. Beta- and alpha-carotene can act as precursors for the synthesis of vitamin A. The dietary carotenoid (beta-carotene) is found in red, orange, yellow and leafy green vegetables (e.g. carrots, sweet potato, silverbeet) and red and orange fruit (e.g. mangos, oranges).</P>
<P>Vitamin A deficiency can be defined as serum retinol (SROL) concentration less than 0.70 µmol/L (less than 20 µg/dl) (<LINK REF="REF-West-2003" TYPE="REFERENCE">West 2003</LINK>). However, SROL levels may be influenced by albumin and retinol binding protein (RBP) as well as acute illnesses with infection and inflammation (<LINK REF="REF-Napoli-1996" TYPE="REFERENCE">Napoli 1996</LINK>; <LINK REF="REF-Stephensen-1994" TYPE="REFERENCE">Stephensen 1994</LINK>). SROL levels should be measured during clinical stability (<LINK REF="REF-DAA-2006" TYPE="REFERENCE">DAA 2006</LINK>).</P>
<P>The major consequence of vitamin A deficiency is ocular (eye) with abnormal dark adaptation (night blindness), conjunctival and corneal xerosis (thickening) which can lead to blindness (<LINK REF="REF-DAA-2006" TYPE="REFERENCE">DAA 2006</LINK>; <LINK REF="REF-West-2003" TYPE="REFERENCE">West 2003</LINK>). Another consequence of vitamin A deficiency is the skin condition phrynoderma (a form of follicular hyperkeratosis associated with some micronutrient deficiencies). Vitamin A deficiency has also been linked to impaired mechanisms of host resistance to infection, poor growth and increased mortality in a study of mothers and children (<LINK REF="REF-West-2003" TYPE="REFERENCE">West 2003</LINK>).</P>
<P>On the other hand, hypervitaminosis A (excess levels of vitamin A) is associated with hepatotoxicity and bone problems (<LINK REF="REF-Brei-2013" TYPE="REFERENCE">Brei 2013</LINK>). Also, cross-sectional studies have reported that up to 25% of children with CF do not require vitamin A supplementation as sufficient amounts were already available though their diet (<LINK REF="REF-Brei-2013" TYPE="REFERENCE">Brei 2013</LINK>; <LINK REF="REF-Graham_x002d_Maar-2006" TYPE="REFERENCE">Graham-Maar 2006</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-06-07 14:36:10 +0100" MODIFIED_BY="Anne B Chang">
<P>Vitamin A is available as a sole supplement as well as in combination form with other vitamins as multi-vitamins (either as a liquid or a tablet). The availability of different formulations differ in different health services (<LINK REF="REF-Graham_x002d_Maar-2006" TYPE="REFERENCE">Graham-Maar 2006</LINK>). Vitamin A is usually administered as a daily dose, but the recommended doses vary in different guidelines. For example, the Royal Brompton Hospital guidelines recommend 4000 IU for children aged under one year, then 4000 to 10,000 IU for all other age groups (<LINK REF="REF-Royal-Brompton-Hospital-2011" TYPE="REFERENCE">Royal Brompton Hospital 2011</LINK>); and the USA guidelines recommend 3000 &#956;g retinol activity equivalents (approximately 10,000 IU) (<LINK REF="REF-Graham_x002d_Maar-2006" TYPE="REFERENCE">Graham-Maar 2006</LINK>). </P>
</INTERVENTION>
<THEORY MODIFIED="2008-04-14 12:10:25 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Normalisation of vitamin A levels may avoid the afore-mentioned problems. However supplementation of these vitamins to excessive levels may cause harm to the respiratory system, the skeletal system (osteoporosis and fractures) and liver abnormality (<LINK REF="REF-Penniston-2006" TYPE="REFERENCE">Penniston 2006</LINK>) in children with and without CF (<LINK REF="REF-Graham_x002d_Maar-2006" TYPE="REFERENCE">Graham-Maar 2006</LINK>; <LINK REF="REF-Sethuraman-2006" TYPE="REFERENCE">Sethuraman 2006</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-05-12 10:35:09 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The approach of addressing the possibility of the development deficiency of these fat-soluble vitamins is variable among CF centres. While vitamin A deficiency maybe a problem, excess supplementation causing chronic hypervitaminosis A may also occur. Thus a systematic review on the efficacy of vitamins A, D, E and K supplementation in children and adults with CF in preventing effects of the deficiency of these vitamins would help guide clinical practice. Supplementation of vitamins D, E and K will be addressed in other Cochrane Systematic Reviews (<LINK REF="REF-Ferguson-2012" TYPE="REFERENCE">Ferguson 2012</LINK>; <LINK REF="REF-Jagannath-2013" TYPE="REFERENCE">Jagannath 2013</LINK>; <LINK REF="REF-Okebukola-2011" TYPE="REFERENCE">Okebukola 2011</LINK>; <LINK REF="REF-Shamseer-2010" TYPE="REFERENCE">Shamseer 2010</LINK>). This review will evaluate vitamin A supplementation in children and adults with CF. This version of the review is an update of previous versions (<LINK REF="REF-Bonifant-2012" TYPE="REFERENCE">Bonifant 2012</LINK>; <LINK REF="REF-O_x0027_Neil-2008" TYPE="REFERENCE">O'Neil 2008</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-04-10 12:55:07 +0100" MODIFIED_BY="Nikki Jahnke">
<P>To determine if vitamin A supplementation in children and adults with CF:</P>
<OL>
<LI>reduces the frequency of vitamin A deficiency disorders;</LI>
<LI>improves general and respiratory health;</LI>
<LI>increases the frequency of vitamin A toxicity.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2014-04-08 16:48:56 +0100" MODIFIED_BY="Nikki Jahnke">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised (RCTs) and quasi-randomised trials (controlled clinical trials).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Children or adults with CF (defined by sweat tests or genetic testing) with and without pancreatic insufficiency.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>All preparations of oral vitamin A used as a supplement compared to either no supplementation or placebo at any dose for at least three months.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-04-10 12:59:17 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We planned to obtain data on at least one of the following outcome measures:</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-04-10 12:56:59 +0100" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>Vitamin A deficiency disorders</LI>
<OL>
<LI>visual impairment</LI>
<LI>any other ocular dysfunction</LI>
<LI>skin manifestations (e.g. phrynoderma)</LI>
</OL>
<LI>Growth and nutritional status (e.g. weight, height, body mass index, z score for weight, etc.)</LI>
<LI>Mortality</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-04-10 12:59:11 +0100" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>Respiratory outcomes</LI>
<OL>
<LI>bronchiectasis severity control (e.g. Likert scale, visual analogue scale or radiological score (<LINK REF="REF-Marchant-2001" TYPE="REFERENCE">Marchant 2001</LINK>))</LI>
<LI>lung function indices (spirometry e.g. FEV<SUB>1</SUB> and FVC)</LI>
<LI>proportions of participants who had respiratory exacerbations or hospitalisations or both</LI>
<LI>total number of hospitalised days or days off work or school</LI>
</OL>
<LI>Quality of life</LI>
<LI>Adverse events (e.g. vomiting, loss of appetite, osteoporosis, fractures or any other adverse event noted)</LI>
<LI>Possible toxicity events (e.g. liver dysfunction)</LI>
<LI>Measured levels of vitamin A</LI>
</OL>
<P>We planned to evaluate outcomes based on</P>
<OL>
<LI>short term (12 months or less), and</LI>
<LI>medium to long term (longer than one year)</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-04-08 16:48:56 +0100" MODIFIED_BY="Nikki Jahnke">
<ELECTRONIC_SEARCHES MODIFIED="2014-04-08 16:48:56 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We attempted to identify relevant studies from the Group's Cystic Fibrosis Trials Register using the term 'vitamin A'.</P>
<P>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <I>The Cochrane Library</I>), quarterly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals - <I>Pediatric Pulmonology </I>and the <I>Journal of Cystic Fibrosis</I>. Unpublished work is identified by searching through the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html">Cystic Fibrosis and Genetic Disorders Group Module</A>.</P>
<P>Date of the most recent search of the Group's Cystic Fibrosis Trials Register: 07 April 2014.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-04-10 12:59:43 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Searches of bibliographies and texts of selected studies were also conducted to identify additional studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-06-07 11:30:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The authors did not apply the process described below since no studies were identified. In future updates of this review, the authors will apply the following methods if studies are identified:<B>
<I> </I>
</B>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2008-04-10 13:02:35 +0100" MODIFIED_BY="Nikki Jahnke">
<P>From the title, abstract, or descriptors, two authors will independently review results of the literature searches to identify studies potentially relevant to the review according to our inclusion criteria for further assessment. From these studies, the same two authors will independently examine the papers in further detail in order to select studies for inclusion using the criteria stated before. The authors will resolve disagreement by consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-04-10 13:04:51 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The authors will review studies that satisfy the inclusion criteria for the review and independently extract data on the outcomes described as follows: study setting; year of study; source of funding; participant recruitment details (including number of eligible participants); inclusion and exclusion criteria; randomisation and allocation concealment method; numbers of participants randomised; blinding (masking) of participants, care providers and outcome assessors; dose and type of intervention; duration of therapy; co-interventions; numbers of participants not followed up; reasons for withdrawals from study protocol (clinical, side effects, refusal and other); side effects of therapy; and whether intention-to-treat analyses were possible.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-05-31 13:02:18 +0100" MODIFIED_BY="Nikki Jahnke">
<P>In order to assess the risk of bias, two review authors will independently assess the quality of the studies included in the review according to the criteria described by Jüni (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>):</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>The authors will assess allocation concealment in each study as follows:</P>
<OL>
<LI>adequate, if the allocation of participants involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed opaque envelopes;</LI>
<LI>unclear, if the method used to conceal the allocation was not described;</LI>
<LI>inadequate, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Generation of the allocation sequence</HEADING>
<P>The authors will grade each study for allocation concealment as follows:</P>
<OL>
<LI>adequate, if methods of randomisation include using a random number table, computer-generated lists or similar methods;</LI>
<LI>unclear, if the study is described as randomised, but no description of the methods used to allocate participants to treatment group was described;</LI>
<LI>inadequate, if methods of randomisation include alternation; the use of case record numbers, dates of birth or day of the week, and any procedure that is entirely transparent before allocation.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding (or masking)</HEADING>
<P>The authors will grade each study for blinding as follows:</P>
<OL>
<LI>blinding of clinician (person delivering treatment) to treatment allocation;</LI>
<LI>blinding of participant to treatment allocation;</LI>
<LI>blinding of outcome assessor to treatment allocation.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Follow-up</HEADING>
<P>The authors will grade each study as to whether numbers of and reasons for dropouts and withdrawals in all intervention groups were described; or if it was specified that there were no dropouts or withdrawals.</P>
<P>They will also report on whether the investigators had performed a sample-size calculation and if they used an intention-to-treat (ITT) analysis.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-05-31 13:05:56 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The authors will include the results from studies that meet the inclusion criteria and report any of the outcomes of interest in the subsequent meta-analyses if any data are applicable.</P>
<P>For the dichotomous outcome variables of each individual study, they will calculate the odds ratio (OR) using a modified ITT analysis, i.e. if the original investigators did not use ITT analysis, they will consider dropouts to be failures. They will also calculate the summary weighted odds ratios and 95% confidence intervals (CIs) (fixed-effect model) using RevMan (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). The authors will calculate numbers-needed-to-treat (NNT) and their 95% CIs from the pooled OR and its 95% CI for a specific baseline risk, which is the sum of all the events in the control groups (in all studies) divided by the total participant numbers in control groups in all studies using an online calculator (<LINK REF="REF-Cates-2003" TYPE="REFERENCE">Cates 2003</LINK>).</P>
<P>For continuous outcomes, they will record the mean relative change from baseline for each group or mean post-treatment or post-intervention values and standard deviation. If standard errors are reported, they will calculate the standard deviations. The authors will then calculate a pooled estimate of treatment effect by the weighted mean difference and 95% confidence interval (fixed-effect model) again using RevMan (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-05-31 13:06:32 +0100" MODIFIED_BY="Nikki Jahnke">
<P>For cross-over studies, the authors will calculate the mean treatment differences where possible and enter these using the fixed-effect generic inverse variance (GIV) analysis in RevMan, to provide summary weighted differences and 95% CIs (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). In cross-over studies, if they believe there is a carryover effect which will outlast any washout period included in the study, they will include only data from the first arm in the meta-analysis (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>).</P>
<P>If studies report outcomes using different measurement scales, the authors will estimate the standardised mean difference and 95% CIs.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-04-10 13:05:20 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The authors will request further information from the primary investigators where required.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-05-31 13:07:25 +0100" MODIFIED_BY="Nikki Jahnke">
<P>They will describe any heterogeneity between the study results and test this to see if it reached statistical significance using the chi-squared test. They will consider heterogeneity to be significant when the P value is less than 0.10 (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The authors also plan to use the I<SUP>2</SUP> statistic where heterogeneity is categorised such that a value of under 25% is considered low, around 50% is considered moderate and over 75% is considered a high degree of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-05-31 13:09:18 +0100" MODIFIED_BY="Anne B Chang">
<P>The authors will include the 95% CI, estimated using a fixed-effect model. However, they will utilise the random-effects model whenever there are concerns about statistical heterogeneity.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-06-07 11:30:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The authors plan to perform the following <I>a priori </I>subgroup analyses to investigate any heterogeneity which they identify.</P>
<OL>
<LI>children (aged 18 years or less) and adults (over 18 years);</LI>
<LI>formulations of the vitamin (single or multivitamin);</LI>
<LI>presence of significant liver synthetic dysfunction (low baseline albumin);</LI>
<LI>presence of previous bowel resections;</LI>
<LI>presence of pancreatic insufficiency;</LI>
<LI>method of CF diagnosis (i.e. screening versus symptomatic diagnosis).</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-04-10 14:05:43 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Sensitivity analyses are also planned to assess the impact of the potentially important factors on the overall outcomes:</P>
<OL>
<LI>analysis using a random-effects model;</LI>
<LI>analysis by "treatment received" (as opposed to ITT analysis).</LI>
</OL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-05-31 13:10:55 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY_DESCRIPTION MODIFIED="2012-05-31 13:10:17 +0100" MODIFIED_BY="Nikki Jahnke">
<SEARCH_RESULTS MODIFIED="2012-05-31 13:10:17 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The authors identified a single study in our searches (<LINK REF="STD-Wood-2003" TYPE="STUDY">Wood 2003</LINK>).</P>
</SEARCH_RESULTS>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-12-03 15:53:56 +0000" MODIFIED_BY="Nikki Jahnke">
<P>The only study identified was excluded because it was not placebo controlled (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-05-31 13:10:41 +0100" MODIFIED_BY="Tracey Remmington">
<P>The authors did not find any eligible studies that fulfilled the inclusion criteria.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-05-31 13:10:55 +0100" MODIFIED_BY="Tracey Remmington">
<P>The authors did not find any eligible studies that fulfilled the inclusion criteria.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-05-13 12:11:46 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Daily vitamin A supplementation is almost universally recommended for people with CF who are pancreatic insufficient. However, it is unfortunate that there are no controlled studies that have examined this. The appropriate dose and frequency of vitamin A supplementation is also unknown. Furthermore while vitamin A deficiency causes eye and skin disorders, excess vitamin A can also cause problems (<LINK REF="REF-Griffiths-2000" TYPE="REFERENCE">Griffiths 2000</LINK>; <LINK REF="REF-Penniston-2006" TYPE="REFERENCE">Penniston 2006</LINK>). Indeed, increasingly data on micronutrients have shown that micronutrient supplementation is only beneficial in states of deficiency and harmful when no deficiency exists (<LINK REF="REF-Chang-2006" TYPE="REFERENCE">Chang 2006</LINK>; <LINK REF="REF-Shenkin-2006" TYPE="REFERENCE">Shenkin 2006</LINK>). For vitamin A, Griffiths has termed this the 'vitamin A paradox' as vitamin A supplementation is likely to be "protective against pneumonia in malnourished children (who are likely to be vitamin A-deficient) and is paradoxically detrimental for adequately nourished children" (<LINK REF="REF-Griffiths-2000" TYPE="REFERENCE">Griffiths 2000</LINK>).</P>
<P>It is well accepted that people with CF and pancreatic insufficiency are at risk of vitamin A deficiency. However, this is now a rare occurrence (<LINK REF="REF-Brei-2013" TYPE="REFERENCE">Brei 2013</LINK>); and it is also biologically plausible that currently, with improved pancreatic replacement therapies and attention to macro-nutrition and caloric supplements, the majority of people with CF are vitamin A sufficient and may not require daily vitamin A supplementation. Daily supplementation in these situations may cause no harm, but it adds a further burden to the daily medical regimen of people with CF, and it is possible that it may be biologically harmful. Thus, some have called for individualised supplementation based on annual measurements rather than a fixed dosage as is currently recommended in most CF guidelines (<LINK REF="REF-Brei-2013" TYPE="REFERENCE">Brei 2013</LINK>). Furthermore, current guidelines "do not take into account the specific formulation of vitamin A supplementation, such as water-soluble or fat-soluble retinol and beta-carotene. Water-soluble preparations pose more risks to CF patients than fat-soluble preparations, because they are more easily absorbed in patients with pancreatic insufficiency" (<LINK REF="REF-Brei-2013" TYPE="REFERENCE">Brei 2013</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-04-09 15:15:21 +0100" MODIFIED_BY="Nikki Jahnke">
<IMPLICATIONS_PRACTICE MODIFIED="2014-04-09 15:15:08 +0100" MODIFIED_BY="Nikki Jahnke">
<P>As there were no randomised or quasi-randomised controlled trials identified, we cannot draw any conclusions on the benefits (or otherwise) of regular administration of vitamin A in people with CF. Until further data are available, country or region specific guidelines (e.g. UK CF Trust Nutrition Guidelines (<LINK REF="REF-CF-Trust-2002" TYPE="REFERENCE">CF Trust 2002</LINK>)) on the use and monitoring of vitamin A in people with CF should be followed.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-04-09 15:15:21 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The need for a well-designed, parallel, adequately-powered, multi-centre, randomised controlled trial to assess if vitamin A supplementation in children and adults with CF is beneficial or otherwise, is obvious. The study should examine if vitamin A supplementation positively or negatively influences the frequency of symptoms of vitamin A deficiency or general and respiratory outcomes. The possible negative effects should be examined in light of recent data showing possible harm when micronutrients are used in people who are not micronutrient-deficient. Safety monitoring during such a study would be important as the current practice is to use supplementation of vitamin A in people with CF. Vitamin A levels should be measured before and during the studies when clinically stable and related to serum albumin and retinol binding protein. Studies involving both children and adults are required and results should be related to nutritional status and pancreatic status. Data relating to appropriate dose, frequency of supplementation and type of formulation of vitamin A (water-soluble, fat-soluble, beta carotene) are also needed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-04-09 15:15:48 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We thank Nikki Jahnke and Dr Gerard Ryan from the Cochrane Cystic Fibrosis &amp; Genetic Disorders Group for their advice, supportive role and comments to the protocol and review and to Natalie Hall for help with the searches.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-05-06 10:50:18 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Catherine Bonifant has no potential conflict of interest.</P>
<P>Anne Chang declares the receipt of a grant provided by GSK, which is however unrelated to this topic.</P>
<P>Elizabeth Shevill has no potential conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-05-06 10:48:46 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Protocol: CB and AC wrote the protocol. ES reviewed the protocol.</P>
<P>Original review: When any studies are identified, CB and AC will select relevant studies, perform data extraction and analysis and write the review. ES will contribute to writing of the review. </P>
<P>Updated reviews: AC updated the reviews with the help of Nikki Jahnke.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-04-09 15:09:07 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDIES MODIFIED="2009-12-03 13:22:02 +0000" MODIFIED_BY="Anne B Chang">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2009-12-03 13:22:02 +0000" MODIFIED_BY="Anne B Chang">
<STUDY DATA_SOURCE="PUB" ID="STD-Wood-2003" MODIFIED="2009-12-03 13:22:02 +0000" MODIFIED_BY="Anne B Chang" NAME="Wood 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-12-03 13:22:02 +0000" MODIFIED_BY="Anne B Chang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wood LG, Fitzgerald DA, Lee AK, Garg ML</AU>
<TI>Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>77</VL>
<NO>1</NO>
<PG>150-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-04-09 15:09:07 +0100" MODIFIED_BY="Nikki Jahnke">
<ADDITIONAL_REFERENCES MODIFIED="2014-04-09 15:09:07 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Brei-2013" MODIFIED="2014-04-09 14:59:45 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Brei 2013" TYPE="JOURNAL_ARTICLE">
<AU>Brei C, Simon A, Krawinkel MB, Naehrlich L</AU>
<TI>Individualized vitamin A supplementation for patients with cystic fibrosis</TI>
<SO>Clinical Nutrition (Edinburgh, Scotland)</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>5</NO>
<PG>805-10</PG>
<IDENTIFIERS MODIFIED="2014-04-09 02:14:25 +0100" MODIFIED_BY="Anne Chang">
<IDENTIFIER MODIFIED="2014-04-09 02:14:25 +0100" MODIFIED_BY="Anne Chang" TYPE="DOI" VALUE="10.1016/j.clnu.2013.01.009"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cates-2003" NAME="Cates 2003" TYPE="COMPUTER_PROGRAM">
<TI>Visual Rx. Online NNT Calculator</TI>
<YR>2003</YR>
<PB>Cates C</PB>
<CY>www.nntonline.net/</CY>
<MD>Internet</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CF-Trust-2002" NAME="CF Trust 2002" TYPE="OTHER">
<AU>UK Cystic Fibrosis Trust Nutrition Working Group</AU>
<TI>Nutritional management of cystic fibrosis</TI>
<SO>UK Cystic Fibrosis Trust Consensus Document on Nutritional Management</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2006" NAME="Chang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chang AB, Torzillo PJ, Boyce NC, White AV, Stewart PA, Wheaton GR, et al</AU>
<TI>Zinc and Vitamin-A supplementation in Indigenous children hospitalised with episodes of lower respiratory tract infection: a randomised controlled trial</TI>
<SO>Medical Journal of Australia</SO>
<YR>2006</YR>
<VL>184</VL>
<NO>3</NO>
<PG>107-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DAA-2006" MODIFIED="2012-06-07 14:43:32 +0100" MODIFIED_BY="Nikki Jahnke" NAME="DAA 2006" TYPE="OTHER">
<AU>Dietitians Association of Australia</AU>
<TI>National Cystic Fibrosis Interest Group. Australasian Clinical Practice Guidelines for Nutrition in Cystic Fibrosis</TI>
<SO>www.cysticfibrosis.org.au/books/nutritionbooks/</SO>
<YR>(accessed 06 December 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dodge-2006" NAME="Dodge 2006" TYPE="JOURNAL_ARTICLE">
<AU>Dodge JA, Turck D</AU>
<TI>Cystic fibrosis: nutritional consequences and management</TI>
<SO>Best Practice &amp; Research. Clinical Gastroenterology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>3</NO>
<PG>531-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferguson-2012" MODIFIED="2012-05-24 08:59:21 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Ferguson 2012" TYPE="COCHRANE_REVIEW">
<AU>Ferguson JH, Chang AB</AU>
<TI>Vitamin D supplementation for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-05-24 08:53:02 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-05-24 08:53:02 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD007298.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Graham_x002d_Maar-2006" NAME="Graham-Maar 2006" TYPE="JOURNAL_ARTICLE">
<AU>Graham-Maar RC, Schall JI, Stettler N, Zemel BS, Stallings VA</AU>
<TI>Elevated vitamin A intake and serum retinol in preadolescent children with cystic fibrosis</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>84</VL>
<NO>1</NO>
<PG>174-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffiths-2000" NAME="Griffiths 2000" TYPE="JOURNAL_ARTICLE">
<AU>Griffiths JK</AU>
<TI>The vitamin A paradox</TI>
<SO>Journal of Pediatrics</SO>
<YR>2000</YR>
<VL>137</VL>
<NO>5</NO>
<PG>604-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-31 13:08:44 +0100" MODIFIED_BY="Tracey Remmington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.1 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jagannath-2013" MODIFIED="2014-04-09 15:09:07 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Jagannath 2013" TYPE="COCHRANE_REVIEW">
<AU>Jagannath VA, Fedorowicz Z, Thaker V, Chang AB</AU>
<TI>Vitamin K supplementation for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-04-09 15:09:06 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2014-04-09 15:09:06 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD008482.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marchant-2001" NAME="Marchant 2001" TYPE="JOURNAL_ARTICLE">
<AU>Marchant JM, Masel JP, Dickinson FL, Masters IB, Chang AB</AU>
<TI>Application of chest high-resolution computer tomography in young children with cystic fibrosis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>31</VL>
<NO>1</NO>
<PG>24-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Napoli-1996" NAME="Napoli 1996" TYPE="JOURNAL_ARTICLE">
<AU>Napoli JL</AU>
<TI>Retinoic acid biosynthesis and metabolism</TI>
<SO>The FASEB journal : official publication of the Federation of American Societies for Experimental Biology</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>9</NO>
<PG>993-1001</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Okebukola-2011" MODIFIED="2012-05-24 08:56:47 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Okebukola 2011" TYPE="COCHRANE_PROTOCOL">
<AU>Okebukola PO, Kansra S, McCabe H</AU>
<TI>Vitamin E supplementation in people with cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2012-05-24 08:56:47 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-05-24 08:56:47 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD009422"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Penniston-2006" NAME="Penniston 2006" TYPE="JOURNAL_ARTICLE">
<AU>Penniston KL, Tanumihardjo SA</AU>
<TI>The acute and chronic toxic effects of vitamin A</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>83</VL>
<NO>2</NO>
<PG>191-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-05-31 13:04:19 +0100" MODIFIED_BY="Nikki Jahnke" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>Version 5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royal-Brompton-Hospital-2011" MODIFIED="2012-06-07 11:34:08 +0100" MODIFIED_BY="[Empty name]" NAME="Royal Brompton Hospital 2011" TYPE="OTHER">
<TI>Clinical Guidelines: Care of Children with Cystic Fibrosis: Royal Brompton Hospital (5th edition) 2011</TI>
<SO>www.rbht.nhs.uk/childrencf</SO>
<YR>(accessed 06 June 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sethuraman-2006" NAME="Sethuraman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sethuraman U</AU>
<TI>Vitamins</TI>
<SO>Pediatric Review</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>2</NO>
<PG>44-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shamseer-2010" MODIFIED="2012-05-24 08:59:48 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Shamseer 2010" TYPE="COCHRANE_REVIEW">
<AU>Shamseer L, Adams D, Brown N, Johnson JA, Vohra S</AU>
<TI>Antioxidant micronutrients for lung disease in cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2012-05-24 08:54:21 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-05-24 08:54:21 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD007020.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shenkin-2006" NAME="Shenkin 2006" TYPE="JOURNAL_ARTICLE">
<AU>Shenkin A</AU>
<TI>The key role of micronutrients</TI>
<SO>Clinical Nutrition</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>1</NO>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stephensen-1994" NAME="Stephensen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Stephensen CB, Alvarez JO, Kohatsu J, Hardmeier R, Kennedy JI Jr, Gammon RB Jr</AU>
<TI>Vitamin A is excreted in the urine during acute infection</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1994</YR>
<VL>60</VL>
<NO>3</NO>
<PG>388-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-West-2003" MODIFIED="2012-06-07 14:44:04 +0100" MODIFIED_BY="Nikki Jahnke" NAME="West 2003" TYPE="JOURNAL_ARTICLE">
<AU>West KP Jnr</AU>
<TI>Vitamin A deficiency disorders in children and women</TI>
<SO>Food and Nutrition Bulletin</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>4 Suppl</NO>
<PG>S78-90</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-04-09 15:07:38 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Bonifant-2012" MODIFIED="2014-04-09 15:07:38 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Bonifant 2012" TYPE="COCHRANE_REVIEW">
<AU>Bonifant CM, Shevill E, Chang AB</AU>
<TI>Vitamin A supplementation for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>8</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006751.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Neil-2008" MODIFIED="2012-05-23 17:16:30 +0100" MODIFIED_BY="Nikki Jahnke" NAME="O'Neil 2008" TYPE="COCHRANE_REVIEW">
<AU>O'Neil CM, Shevill E, Chang AB</AU>
<TI>Vitamin A supplementation for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-05-23 17:16:30 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-05-23 17:16:30 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD006751.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2014-04-09 15:07:38 +0100" MODIFIED_BY="Nikki Jahnke"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-05-06 10:50:44 +0100" MODIFIED_BY="Nikki Jahnke">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-05-06 10:50:44 +0100" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-05-06 10:50:34 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Wood-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-06 10:50:34 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Non-placebo controlled trial. This trial examined outcomes of 46 CF patients randomly assigned to either group A [low dose of supplement (10 mg vitamin E and 500 micro g vitamin A)] or group B [high dose of supplement (200 mg vitamin E, 300 mg vitamin C, 25 mg beta-carotene, 90 micro g Se, and 500 micro g vitamin A)].</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CF: cystic fibrosis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>